Release issued 25th June 2008

Physician treatment patterns and drivers will vary by geographic location, according to a new report by Decision Resources

June 25, 2008-Waltham, Mass. Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the Chinese Renal Cell Carcinoma drug market will grow more than five-fold by 2012, from US$ 11 million in 2007 to US$ 57 million in 2012. According to the new Emerging Markets report entitled Renal Cell Carcinoma in China, this growth will be fueled by the introduction of novel targeted agents, patients' increasing access to medical care and the increasing incidence of Renal Cell Carcinoma.

Additionally, the report finds that the incidence of Renal Cell Carcinoma in China was 29,000 cases in 2007. This figure will exceed 57,000 by 2017 in part due to urbanization, changes in population demographics and increases in risk factors such as obesity.

"We expect the Chinese government to unveil a plan for healthcare reform in 2008," said Victor Li, Ph.D., analyst at Decision Resources. "Given the significant efficacy of targeted therapies for Renal Cell Carcinoma, the government is under pressure from physicians and patients to reimburse these agents. The patient shares of those targeted Renal Cell Carcinoma therapies included in the government reimbursement list, are expected to increase significantly."

The report also finds that the most important issues in treating Renal Cell Carcinoma are the need for more-effective therapies and the need for clinical trials of therapies that involve Chinese patients. Physician opinion on these issues varies widely by geographic location-physicians in Beijing and Shanghai cite more-efficacious therapies as the most important need, while physicians in Guangzhou consider the lack of clinical trials for Renal Cell Carcinoma therapies the most important unmet need.

About Emerging Markets - China
Emerging Markets - China is the first and only syndicated report series focusing on high-growth emerging markets with comprehensive disease-specific analysis. With these reports, biopharmaceutical companies can accomplish the following:

• More accurately assess the commercial opportunity for Western brands in key pharmaceutical markets of China - Beijing, Shanghai, Guangzhou - and in the high-growth second-tier markets of Tianjin, Wuhan, Nanjing, Hangzhou, and Jinan
• Understand the physician treatment patterns and drivers of choice in key first- and second-tier cities based on primary research
• Gain a clear perspective of the Chinese five-year market forecast at the drug level, broken out by urban and rural areas, and by sales from multinational and Chinese-based companies

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

(26th August 2008) Half of surveyed physicians expect to replace between 6 percent and 15 percent of their Sustiva prescriptions with Isentress

(21st August 2008) Pharmacogenomics-based drug development holds promise

(18th August 2008) India’s hepatitis b virus drug market will grow ten-fold by 2012

(14th August 2008) Relative to their population size, New England states should support largest markets for dyslipidemia drugs

(13th August 2008) Launches of Humira, Golimumab and Orencia for treatment of ulcerative colitis will drive annual five percent market growth